nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

14.01.2022 | short review

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

verfasst von: Johannes Schöche, Dora Niedersüß-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

Agents targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) are part of systemic therapy in advanced colorectal cancer. It is well known that only certain molecular subpopulations profit from EGFR antibodies, restricting those therapeutics to a smaller fraction of patients. Recently investigated, the monitoring of temporally changing RAS mutational status by liquid biopsy might allow the application of EGFR antibodies to an additional subset of patients. In addition, KRAS G12C inhibitors combined with anti-EGFR antibodies are currently under investigation in clinical trials and could provide another effective therapy in case of KRAS G12C mutations. Beyond RAS, therapy guided by microsatellite instability (MSI) status, BRAF mutations, HER2 overexpression and NTRK fusions are welcome additions to targeted treatment in advanced colorectal cancer.

Vorheriger Artikel Practice-changing strategies in the treatment of esophageal cancer

Nächster Artikel Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

In the following, under the generalized term “RAS mutated”, named mutations will be subsided.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. https://doi.org/10.1016/S0140-6736(19)32319-0.CrossRefPubMed

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. https://doi.org/10.1056/NEJMoa032691.CrossRefPubMed

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17. https://doi.org/10.1056/NEJMoa0805019.CrossRefPubMed

Zheng B, Wang X, Wei M, Wang Q, Li J, Bi L, et al. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):1–12. https://doi.org/10.1186/s12885-019-5481-z.CrossRef

Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K‑ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.CrossRefPubMed

van Cutsem E, Köhne C‑H, Hitre E, Zaluski J, Chang Chien C‑R, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–17.CrossRefPubMed

de Roock W, Claes B, Bernasconi D, de Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.CrossRefPubMed

Douillard J‑Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.CrossRefPubMed

10.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888.CrossRefPubMedPubMedCentral

11.

Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, et al. BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. J Natl Cancer Inst. 2021;113(10):1386–95. https://doi.org/10.1093/jnci/djab042.CrossRefPubMed

12.

Pietrantonio F, Petrelli F, Coinu A, di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587–94.CrossRefPubMed

13.

Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Euker J, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE‑4.5 study (AIO KRK-0116). J Clin Oncol. 2021;39(15_suppl):3502. https://doi.org/10.1200/JCO.2021.39.15_suppl.3502.CrossRef

14.

Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of innate and acquired resistance to anti-EGFR therapy: a review of current knowledge with a focus on rechallenge therapies. Clin Cancer Res. 2019;25(23):6899.CrossRefPubMedPubMedCentral

15.

Arnold D, Lueza B, Douillard J‑Y, Peeters M, Lenz H‑J, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713.CrossRefPubMedPubMedCentral

16.

Boeckx N, Janssens K, Van Camp G, et al. The predictive value of primary tumor location in patients with metastatic colorectal cancer: a systematic review. Crit Rev Oncol Hematol. 2018;121:1–10. https://doi.org/10.1016/j.critrevonc.2017.11.003.CrossRefPubMed

17.

André T, Shiu K‑K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–18.CrossRefPubMed

18.

Le DT, Kim TW, van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9. https://doi.org/10.1200/JCO.19.02107.CrossRefPubMed

19.

Cremolini C, Rossini D, Antoniotti C, Pietrantonio F, Lonardi S, Salvatore L, et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32:S1294–S5. https://doi.org/10.1016/j.annonc.2021.08.2094.CrossRef

20.

Tabernero J, Grothey A, van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273–84. https://doi.org/10.1200/JCO.20.02088.CrossRefPubMedPubMedCentral

21.

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–70. https://doi.org/10.1002/path.4679.CrossRefPubMedPubMedCentral

22.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://doi.org/10.1016/S1470-2045(16)00150-9.CrossRefPubMed

23.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518–30. https://doi.org/10.1016/S1470-2045(18)30904-5.CrossRefPubMedPubMedCentral

24.

Yoshino T, di Bartolomeo M, Raghav KPS, Masuishi T, Loupakis F, Kawakami H, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol. 2021;39(15_suppl):3505. https://doi.org/10.1200/JCO.2021.39.15_suppl.3505.CrossRef

25.

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731.CrossRefPubMedPubMedCentral

26.

Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40.CrossRefPubMedPubMedCentral

27.

Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40.CrossRefPubMedPubMedCentral

28.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795–801.CrossRefPubMedPubMedCentral

29.

Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53.CrossRefPubMed

30.

Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50.CrossRefPubMed

31.

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Fenocchio E, et al. Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: the CHRONOS trial. J Clin Oncol. 2021;39(15_suppl):3506. https://doi.org/10.1200/JCO.2021.39.15_suppl.3506.CrossRef

32.

ClinicalTrials.gov. Metastatic colorectal cancer (RAS-wildtype) after response to first-line treatment with FOLFIR plus cetuximab. 2021. https://clinicaltrials.gov/ct2/show/NCT02934529. Accessed 22 June 2021.

33.

Arnold D, Prager GW, Quintela A, Stein A, Vera SM, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. Ann Oncol. 2018;29:835–56.CrossRefPubMedPubMedCentral

34.

Henry J, Willis J, Parseghian CM, Raghav KPS, Johnson B, Dasari A, et al. NeoRAS: incidence of RAS reversion from RAS mutated to RAS wild type. J Clin Oncol. 2020;38(4_suppl):180.CrossRef

35.

Klein-Scory S, Wahner I, Maslova M, Al-Sewaidi Y, Pohl M, Mika T, et al. Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer. Front Oncol. 2020;10:1115. https://doi.org/10.3389/fonc.2020.01115.CrossRefPubMedPubMedCentral

36.

Sunakawa Y, Usher J, Satake H, Jaimes Y, Miyamoto Y, Nakamura M, et al. Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation. Ann Oncol. 2018;29:viii181–viii2.CrossRef

37.

Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, et al. NeoRAS wild-type in metastatic colorectal cancer: myth or truth?—Case series and review of the literature. Eur J Cancer. 2021;153:86–95.CrossRefPubMed

38.

Hong DS, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Eng J Med. 2020; https://doi.org/10.1056/NEJMoa1917239.CrossRef

39.

Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. Cancer Discov. 2020;10:1129–68.CrossRefPubMedPubMedCentral

40.

OncologyPRO. KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12. 2021. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/krystal-1-adagrasib-mrtx849-as-monotherapy-or-combined-with-cetuximab-cetux-in-patients-pts-with-colorectal-cancer-crc-harboring-a-krasg12. Accessed 7 Oct 2021.

41.

OncologyPRO. CodeBreaK 101 subprotocol H: phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhib. 2021. https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/codebreak-101-subprotocol-h-phase-ib-study-evaluating-combination-of-sotorasib-soto-a-krasg12c-inhibitor-and-panitumumab-pmab-an-egfr-inhib. Accessed 7 Oct 2021.

42.

Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, et al. KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population. Clin Colorectal Cancer. 2020;19(3):219–25.CrossRefPubMed

43.

Uprety D, Adjei AA. KRAS: from undruggable to a druggable cancer target. Cancer Treat Rev. 2020;89:102070. https://doi.org/10.1016/j.ctrv.2020.102070.CrossRefPubMed

44.

Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.CrossRefPubMed

Titel: Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
verfasst von: Johannes Schöche
Dora Niedersüß-Beke
Publikationsdatum: 14.01.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00787-1

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

original report

Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review

case report

Toxicity management in severe and refractory cases—what we have learned

editorial

Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

Open Access
short review

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Open Access
short review

Immunotherapy—another breakthrough in gastrointestinal malignancies

short review

Springer Medizin Österreich

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

Summary

Weitere Artikel der Ausgabe 1/2022

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review

Toxicity management in severe and refractory cases—what we have learned

Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Immunotherapy—another breakthrough in gastrointestinal malignancies

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review

Toxicity management in severe and refractory cases—what we have learned

Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Immunotherapy—another breakthrough in gastrointestinal malignancies